Home » TEVA GETS APPROVAL FOR GENERIC ZOCOR
TEVA GETS APPROVAL FOR GENERIC ZOCOR
Israel-based Teva has announced that the U.S. FDA has granted tentative approval for its abbreviated new drug application (ANDA) for Simvastatin tablets -- the generic equivalent of Merck's Zocor.
Teva is the first company to apply to market the product in low strengths (5-40 mg.), and will therefore be entitled to 180 days marketing exclusivity, said the company.
The U.S. FDA has filed an appeal to the U.S. Court of Appeals concerning Teva's 180-day exclusivity. Teva expects to receive final approval for the 5 mg, 10 mg, 20 mg, and 40 mg strengths with exclusivity on June 23, when the product patent expires.
KEYWORDS Daily International Pharma Alert
Upcoming Events
-
04Apr
-
11Apr
-
14Apr
-
25Apr
-
14May